IBA ANNOUNCES LEADERSHIP SUCCESSION PLAN

On January 9, IBA announced that Olivier Legrain, IBA Chief Strategy Officer, was taking on the role of Chief Operating Officer as part of a plan to succeed Pierre Mottet as IBA Chief Executive Officer as of May 9 at the company’s shareholder meeting.

Pierre Mottet has worked at IBA for 24 years. Under his leadership, the company developed from a small builder of cyclotrons into an international group of 2,200 professionals recognized for leadership in cancer diagnostics and therapy. At the May 9 meeting, Pierre Mottet will be appointed Vice Chairman of the IBA Board of Directors and become Chairman of the Board in May 2013

Olivier Legrain joined IBA in 1996 as Financial Controller, then became President of the IBA Dosimetry business in 1999, and President of IBA Molecular in 2003, until he was named Chief Strategy Officer in 2010.

Olivier has impressed us with his strategic vision, first in dosimetry and then on a much larger scale in developing an IBA road map and leadership in molecular imaging,” said Mottet. “He is committed to delivering excellent customer service and high-quality work, as well as carrying out the IBA values. I am very confident that under his leadership, IBA will continue to grow and prosper."